Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

GLIOMATCH: Explained with Dr. Kathrin Cresswell

In this episode of the GLIOMATCH: Explained video series, Dr. Kathrin Cresswell, Professor of Digital Innovations in Health and Care at the University of Edinburgh (UEDIN), explains how the social science team explores the pathways to implementation and adoption of GLIOMATCH. We’ve summarised the interview in this news piece.

What are your roles within GLIOMATCH?

Kathrin Cresswell leads the implementation science aspect of GLIOMATCH. Her team works on exploring implementation and adoption processes of the GLIOMATCH platform, including its scalability and long-term sustainability.

What challenges do scientists face when implementing new technology systems?

New technology systems are being developed constantly. The main problem is that most health information technology interventions – between 70 and 90% – fail because people don’t use them. This is due partly to that fact that these new technology systems sometimes create more work, disrupt organisational processes or are simply not deemed necessary to procure by the organisations that could use them. Other times, there might be existing health system factors that impede the implementation and adoption of these new technology systems.

“The majority of health information technology interventions fail because people don't use them. This is exactly what we're trying to avoid with the work we’re doing.”

How is GLIOMATCH working to address technology implementation challenges?

To mitigate the risks associated with known socio-technical challenges from the very beginning, the GLIOMATCH implementation science team is following a set framework rooted in social science. They conduct qualitative research through interviews and observations to analyse how the technology is being conceived and developed. Drawing on lessons from other biotech innovations, they work to understand the potentially unanticipated challenges of implementing GLIOMATCH. They also involve different stakeholders in the research, including patients, carers and healthcare professionals. This collaborative process is designed to increase the likelihood of the GLIOMATCH platform and associated information being adopted and used beyond the research project. Knowledge gained during the project will be compiled in a roadmap for consultation after the study.

What are the implementation goals for the GLIOMATCH platform?

The implementation science team is finding that there are many different visions of where GLIOMATCH can add value, but these differ significantly between interest holders and will likely emerge over long timeframes. Research and clinical applications have different pathways to impact and are interdependent. Real-world impacts are therefore emergent, but depend on stakeholder alignment across clinical, research, organisational, and commercial domains.

“We're co-creating the GLIOMATCH platform with different stakeholders including patients, carers and healthcare professionals, who will then hopefully action the information that GLIOMATCH provides.”

The final publication and video interview will be available on our website shortly. 

In the meantime, we invite you to discover the rest of our GLIOMATCH: Explained series on our video page.

Follow GLIOMATCH on LinkedIn and Facebook for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

More Posts

GLIOMATCH shares its work at the EU Cancer Mission Showcase in Brussels

On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.

Highlights from partner talks at EANO 2026

The KU Leuven team attended EANO 2026 in Rome and Chiara Caprioli and Frederik De Smet presented glioblastoma research and a patient-derived brain tumour model. Discover highlights from the conference.